Drug Profile
Research programme: Sjogren's syndrome diagnostics - Biogen/Oklahoma Medical Research Foundation
Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Biogen
- Developer Biogen; Oklahoma Medical Research Foundation
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Sjogren's syndrome
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for research development in Sjogren's-syndrome(Diagnosis) in USA
- 22 Oct 2015 Early research in Sjogren's syndrome (Diagnosis) in USA (unspecified route)